Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $315.58 Consensus PT from Brokerages
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) have received a consensus rating of “Moderate Buy” from the twenty-six analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-one have assigned a buy rating to the […]
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) have received a consensus rating of “Moderate Buy” from the twenty-six analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-one have assigned a buy rating to the […]